INDIA-EU TRADE VERTICAL FACTSHEET

PHARMACEUTICALS AND ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

This factsheet covers the India-EU pharmaceuticals and APIs trade vertical — market size, key products, regulatory requirements, trade flows, and commercial opportunities for commission-only trade facilitation.

1. Market Overview

2. Key Products and HS Codes

3. EU Regulatory Requirements for Pharma Imports

3.1 Good Manufacturing Practice (GMP)

All pharmaceutical manufacturing facilities in India supplying to the EU must hold a current EU GMP certificate or equivalent certificate issued following an EU GMP inspection. EU GMP inspections are conducted by the national competent authority of the EU member state where the importer holds the marketing authorisation, in collaboration with CDSCO (India's Central Drugs Standard Control Organisation).

EU GMP certificates are issued by EU member state competent authorities (e.g. BfArM in Germany, ANSM in France, HPRA in Ireland) after satisfactory inspection of the Indian manufacturing site.

The EU GMP certificate is site-specific — a separate certificate is required for each manufacturing facility.

The Eudralex Volume 4 (Good Manufacturing Practice Guidelines) sets the EU GMP standards. ICH guidelines (Q7 for APIs, Q8–Q11 for quality by design, Q12 for lifecycle management) are incorporated.

WHO-GMP certification (issued by CDSCO after WHO pre-qualification inspection) is accepted for WHO tender markets but is not a substitute for EU GMP certification for commercial EU sales.

3.2 Marketing Authorisation (MA)

No pharmaceutical product may be placed on the EU market without a Marketing Authorisation. MAs may be obtained through:

Centralised procedure (EMA): For innovative biologics, advanced therapies, and certain mandatory categories. One MA valid across all EU member states.

Decentralised procedure: MA obtained simultaneously in multiple EU member states through mutual recognition of the reference member state's assessment.

National procedure: MA in a single EU member state only — product may not be sold in other member states without further approval.

Parallel import: Import of an EU-approved product from a lower-price member state to a higher-price member state — subject to the parallel importer holding a specific parallel import licence. Indian exporters are typically not involved in parallel import.

For Indian exporters of APIs: The EU importer (typically the finished product manufacturer or MA holder) is responsible for the MA. The Indian API supplier must be approved on the MA dossier as a qualified API manufacturer and must be GMP-compliant.

3.3 Qualified Person (QP) Release

Every batch of a pharmaceutical product sold in the EU must be certified and released by a Qualified Person (QP) — a person with specific pharmaceutical qualifications who is legally responsible for ensuring the batch complies with the specifications and has been manufactured in accordance with GMP. The QP is typically employed by the EU importer or marketing authorisation holder, not the Indian exporter.

3.4 Falsified Medicines Directive (FMD)

Directive 2011/62/EU (FMD) requires all prescription medicines in the EU to carry a unique serial number (serialisation) and tamper-evident packaging. Medicines must be verified at the point of dispensing against the European Medicines Verification System (EMVS). Indian exporters supplying finished formulations for EU retail must ensure serialisation compliance.

4. Trade Facilitation Opportunities

Commission-only trade facilitation in the India-EU pharma vertical focuses on:

API supply mandates: Connecting Indian API manufacturers (particularly in Hyderabad, Ahmedabad, and Aurangabad) with EU finished product manufacturers and MA holders seeking alternative or additional API sources. This is high-value, repeat-business territory — long-term supply agreements are the norm.

Generic formulation mandates: Where an EU importer holds an MA for a generic formulation and is seeking a lower-cost Indian manufacturer to supply under contract manufacturing agreement (toll manufacturing).

Biosimilar supply: Connecting Indian biologics manufacturers (Biocon, Dr. Reddy's, Cipla, Sun Pharma, Lupin) with EU biosimilar marketing authorisation holders for supply of bulk drug substance or finished product.

Herbal and Ayurvedic: Connecting AYUSH-certified Indian manufacturers with EU nutraceutical and herbal supplement importers — a rapidly growing segment.

Key commercial considerations for pharma trade facilitation:

Qualification timeline: EU GMP approval of a new Indian supplier typically takes 12–24 months from initial contact to first approved shipment. Factor this into mandate timelines.

Audit requirements: EU buyers typically conduct a pre-qualification audit of the Indian facility before placing any order. Coordinate audit access as part of the facilitation service.

Long-term contracts: Pharma supply agreements typically run for 2–5 years with annual price review. The commission tail on initial mandates translates into multi-year recurring income.

Regulatory files: The ASMF (Active Substance Master File) or CEP (Certificate of Suitability) held by the Indian API manufacturer is critical to EU buyers — facilitate access to this documentation as part of the introduction process.

5. Key Regulatory Bodies and References

Doc 65 — India-EU Trade Vertical Factsheet: Pharmaceuticals and APIs — Neutral Template